EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Changes in chronic therapies for cystic fibrosis following initiation of CFTR modulators: A UK retrospective cohort study 2009 - 2023

Jordan Busby, Tricia M McKeever, Andrew W Fogarty, Helen L Barr

Journal of Cystic Fibrosis · 2026-09 · 25 (5) · 851-858

DOI: 10.1016/j.jcf.2026.06.003 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Cystic Fibrosis, 2026-09. Verfasst von Jordan Busby und 3 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Nottingham Biomedical Research Centre (BRC) - Respiratory Medicine, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Notting…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Quinolones, Chloride Channel Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Nottingham Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: People with Cystic Fibrosis have a significant treatment burden from large numbers of maintenance therapies required to manage this multi-organ condition. Currently, there are limited data on the impact of CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator use, including Elexacaftor/Tezacaftor/Ivacaftor (ETI), on prescribing of traditional maintenance therapies in the UK. METHODS: Retrospective analysis of chronic medications obtained from UK CF registry data, from 2009 to 2023. Impact of starting ETI on maintenance therapies was analysed using descriptive statistics. For those on ETI, risk factors associated with stopping maintenance treatments were identified by logistic regression models, adjusted for age, sex, and percentage predicted FEV1. Socioeconomic status (SES) was determined by Townsend score quintiles. RESULTS: Overall, chronic medication use decreased for both those prescribed and not prescribed CFTR modulators. Those on ETI, who previously were on dual modulator therapy, had an absolute reduction of 15.1% in inhaled antibiotics, 14.7% in dornase alfa and 9.8% in hypertonic saline by 3 years after ETI initiation. Older age, higher body mass index, and poorer lung function were associated with lower odds of stopping inhaled antibiotics and azithromycin for those on ETI. Those in the lowest SES quintile had significantly lower odds of discontinuing azithromycin (OR:0.61; CI:0.40-0.91) and flucloxacillin (OR:0.54; CI:0.33-0.86), compared to the highest SES quintile. CONCLUSIONS: Overall, prescriptions of traditional maintenance therapies reduced, irrespective of CFTR modulator use. These data suggest deprescribing may have occurred, despite a limited evidence base to support safe antibiotic withdrawal in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorQuinolonesChloride Channel AgonistsHumansRetrospective StudiesUnited KingdomFemaleMaleBenzodioxolesDrug CombinationsAdolescentAdultChildIndolesPyrrolidinesAminophenolsPyrazolesPyridinesQuinolines

Stichwörter der Autor:innen

CFTR modulatorCystic fibrosisETITreatment burden

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorBenzodioxolesDrug CombinationsQuinolonesChloride Channel Agonistselexacaftor, ivacaftor, tezacaftor drug combinationIndolesPyrrolidinesAminophenolsPyrazoles

Autor:innen und Institutionen

  • NIHR Nottingham Biomedical Research Centre (BRC) - Respiratory Medicine, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, United Kingdom; University of Nottingham, School of Medic…

Förderung

  • NIHR Nottingham Biomedical Research Centre

Zitieren

APA

Busby, J., McKeever, T. M., Fogarty, A. W., & Barr, H. L. (2026). Changes in chronic therapies for cystic fibrosis following initiation of CFTR modulators: A UK retrospective cohort study 2009 - 2023. Journal of Cystic Fibrosis, 25(5), 851-858. https://doi.org/10.1016/j.jcf.2026.06.003

Vancouver

Busby J, McKeever TM, Fogarty AW, Barr HL. Changes in chronic therapies for cystic fibrosis following initiation of CFTR modulators: A UK retrospective cohort study 2009 - 2023. Journal of Cystic Fibrosis. 2026;25(5):851-858. doi:10.1016/j.jcf.2026.06.003

BibTeX
@article{Busby2026,
  author = {Busby, Jordan and McKeever, Tricia M and Fogarty, Andrew W and Barr, Helen L},
  title = {Changes in chronic therapies for cystic fibrosis following initiation of CFTR modulators: A UK retrospective cohort study 2009 - 2023},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  volume = {25},
  number = {5},
  pages = {851--858},
  doi = {10.1016/j.jcf.2026.06.003}
}
Kostenlos starten →